Church-based Health Intervention for Cardiovascular Disease
(CHERISH Trial)
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research shows that church-based health programs can help reduce risk factors for heart disease, like high blood pressure and unhealthy weight, especially in communities with a high burden of these conditions. These programs often involve education and lifestyle changes, which have been effective in improving heart health.
12345Church-based health programs have been used to reduce risk factors for cardiovascular disease, such as high blood pressure and unhealthy lifestyle habits, and are generally considered safe for humans.
13467This treatment is unique because it uses church-based programs to deliver health interventions, integrating faith and community support to improve cardiovascular health, especially in high-risk groups like African Americans and rural populations. It combines evidence-based health strategies with spiritual and community elements, which can enhance engagement and effectiveness.
148910Eligibility Criteria
The CHERISH study is for Black or African American adults aged 40 and over who are connected to participating churches in New Orleans. They must have at least four of these risk factors: smoking, obesity, low physical activity, poor diet, high cholesterol, high blood pressure, or elevated blood sugar. Those with recent severe health issues like cancer treatment or heart failure aren't eligible.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Implementation
Participants receive a CHW-led multifaceted intervention or a group-based education strategy to address CVD risk factors
Follow-up
Participants are monitored for sustainability of the intervention and maintenance of cardiovascular health metrics
Participant Groups
Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD is already approved in United States for the following indications:
- Primary prevention of cardiovascular disease